A 17-year-old Aboriginal girl from a remote community has a history of definite acute rheumatic fever and mild rheumatic mitral regurgitation. She is clinically well and lives in a high-incidence region for rheumatic heart disease. According to current Australian rheumatic heart disease guidelines, what is the recommended interval for ongoing secondary prophylaxis with intramuscular benzathine benzylpenicillin G?